Tesamorelin vs AOD-9604: GH Fragment Research Comparison
How researchers compare a full-length GHRH analog to a GH C-terminal fragment in visceral fat and GH axis studies
Tesamorelin and AOD-9604 are both growth hormone-related compounds studied for their effects on body fat composition, but they act through entirely different mechanisms at different points in GH biology. Tesamorelin is a GHRH receptor agonist that stimulates pituitary GH secretion, activating the full GH axis downstream. AOD-9604 is a fragment of the GH protein itself that stimulates adipose lipolysis directly through a peripheral mechanism without engaging the pituitary or the full GH receptor pathway. Researchers choosing between them are effectively choosing whether to study GH axis stimulation or isolated adipose fat metabolism.
At a Glance
Mechanism and research profile for each compound.
Tesamorelin
Tesamorelin activates GHRH receptors on pituitary somatotroph cells, stimulating pulsatile GH release while preserving somatostatin negative feedback. The resulting GH elevation promotes lipolysis in visceral adipose tissue through peripheral GH receptors, and also elevates IGF-1 and produces anabolic effects through downstream GH receptor activation.
AOD-9604
AOD-9604 (HGH residues 176 to 191) stimulates adipose tissue lipolysis through beta-3 adrenergic receptor interaction in adipocytes, without binding the full GH receptor, without elevating IGF-1, and without producing the anabolic or diabetogenic effects of full HGH or GH secretagogues like Tesamorelin.
Key Differences
Side-by-side comparison of key research parameters.
| Aspect | Tesamorelin | AOD-9604 |
|---|---|---|
| Mechanism | GHRH receptor activation, pituitary GH release, downstream GH receptor-mediated effects | Beta-3 adrenergic receptor in adipocytes, direct adipose lipolysis, no GH receptor engagement |
| IGF-1 Effect | Elevates IGF-1 as a consequence of GH axis activation | Does not significantly elevate IGF-1 |
| Pituitary Engagement | Acts at pituitary level; stimulates GH secretion | Does not engage the pituitary; peripheral adipose-specific action |
| Regulatory Status | FDA-approved as Egrifta for HIV lipodystrophy; Phase 3 RCT data (Falutz et al., NEJM 2010) | Not FDA-approved as pharmaceutical; completed Phase 2a obesity trials; FDA GRAS designation |
| Anabolic Effects | Produces anabolic effects through full GH axis activation and IGF-1 elevation | No significant anabolic effects; fat-selective mechanism |
Research Comparison
Tesamorelin and AOD-9604 both produce visceral fat reduction as a documented outcome, but through mechanistically distinct pathways. Tesamorelin does so by activating the pituitary GH axis, producing a broad hormonal response that includes IGF-1 elevation and anabolic effects alongside lipolysis. AOD-9604 does so by directly stimulating adipocyte lipolysis without hormonal axis engagement. Researchers who need to isolate the fat metabolism effect from GH axis hormonal changes would choose AOD-9604; researchers studying full GH axis biology with visceral fat as an outcome would choose Tesamorelin.
Frequently Asked Questions
Explore the Research
Tesamorelin is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.